A short history of left main revascularization: a story of risk. Since its inception in 1960, CABG has been the gold standard for coronary revascularization. Compared with medical therapy alone, CABG lessens both symptoms and mortality in patients with significant stenosis of the LMCA. Medical therapy for patients with LMCA stenosis is abysmal, with a 50% survival at 7 years (2). Conversely, randomized trials consistently show CABG markedly improves survival compared with medical therapy alone. The pain, cost, and recuperation time of CABG were far outweighed by the reduction of risk and improvement of symptoms.
Because it is less painful, less invasive, and has a very short recovery time, PCI has displaced CABG as the primary method for coronary revascularization in patients who have a relatively low inherent risk of infarction and death. In these lower-risk groups (1-or 2-vessel disease, nondiabetic, preserved left ventricular function), early comparative trials of PCI and CABG consistently showed that both techniques lead to similar survival and risk of myocardial infarction (MI), but patients undergoing PCI had more repeat procedures and less angina relief over the long term (3). Patients weighed the outcomes and flocked to PCI because it was less invasive.
As PCI methods improved, its reach extended to more complex coronary disease. The risk of dissection and abrupt closure associated with balloon angioplasty limited its use to fairly limited, discrete coronary lesions. The introduction of bare-metal stents (BMS) reduced periprocedural disasters (coronary occlusion due to dissection) but only modestly reduced the risk of restenosis. This improvement in periprocedural complications led to attempts to treat LMCA lesions with BMS. Among lower-risk patients, bare-metal stenting was associated with lower in-hospital morbidity, but still exposed the individual to a higher risk of unacceptable restenosis and revascularization. Trials in high-risk patients with LMCA disease were met with an unacceptable 13.7% in-hospital mortality and a 24.2% 1-year mortality (4) . At this point in PCI history, the higher risk of PCI outweighed the pain and prolonged recovery of CABG. Consequently, PCI was generally reserved for patients with an unacceptable surgical risk even though it was less invasive.
The development of drug-eluting stents (DES) and advances in bifurcation stenting during the past decade improved both immediate and long-term outcome of LMCA stenting. Six-to 12-month target vessel revascularization (TVR) rates have ranged from 2% to 19% with DES as opposed to 12% to 31% with BMS (5-7). Yet, concerns remain regarding stent thrombosis, particularly when the stent is incompletely apposed to the vessel wall, or dual antiplatelet therapy is not provided. A significant risk of catastrophic left main thrombosis with DES would not outweigh the pain and prolonged recovery of CABG. A health economist would present the composite end point to a patient in practical terms. Recognizing the fact that a patient values survival, morbidity, and discomfort with differing levels of importance, he or she would determine the relative value of the individual end points for a patient using a "standard gamble" or "time-tradeoff" technique. In the process of assigning various weights (Table 1) , the relative value of a stroke, MI, and death could be compared on the same scale. We are not sure what the correct weights are for each aspect of outcome, but considering the relative importance of each would help physicians and patients better assess the results of treatment options. LeMANS (Left Main Angiographic Substudy) (n ϭ 104), the first randomized trial comparing DES with CABG, found no significant difference between the 2 arms in regard to death, MI, or stroke (8) . A subgroup analysis of patients with LMCA disease (n ϭ 705) from the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trial found no significant difference in the composite of death, MI, stroke of repeat revascularization (PCI arm 15.8% vs. CABG arm 13.7%, p ϭ 0.44) (9) . Repeat revascularization occurred more frequently among PCI patients (11.8% vs. 6.5%, p ϭ 0.02). Among patients with coexistent disease involving the LMCA and 2 vessels or 3 vessels, however, the pendulum swung in favor of CABG.
The expansion of PCI into more complex LMCA lesion subsets will require additional randomized clinical trials, and they are underway (EXCEL (1) . Here, we use arbitrary weighting based on the value set of the authors. Using the raw occurrences of the primary composite end point, coronary artery bypass grafting (CABG) appears to be favorable compared to percutaneous coronary intervention (PCI). Using weighted value events occurrences, however, CABG appears to be less favorable. Adding the weighted value of all of the reported complications, PCI appears to be highly favorable compared to CABG. MI ϭ myocardial infarction.
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